ArticleMolecular medicine (Cambridge, Mass.)2025

Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product-receptor axis.

Takanori Matsui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.